Journal
ORGANIC PROCESS RESEARCH & DEVELOPMENT
Volume 11, Issue 2, Pages 246-250Publisher
AMER CHEMICAL SOC
DOI: 10.1021/op6002852
Keywords
-
Categories
Ask authors/readers for more resources
An efficient synthesis of the novel microtubule inhibitor STA-5312 (3-[(4-cyanophenyl)methyl]-N-(3-methyl-5-isothiazolyl)-alpha-oxo-1-indolizineacetamide) was developed. A novel DMF/Me2SO4 directed regioselective synthesis of the 3-(4-cyanobenzoyl)-indolizine (4) was a critical transformation within the four-step process. Alternatively, a CuCl mediated synthesis of 3-(4-cyanobenzyl)indolizine (5) was also developed. All intermediates were obtained in high quality and were used directly for the next step without extensive purification. The drug substance itself was purified by recrystallization from a mixture of THF and water, resulting in a high purity product (HPLC > 98%). The process was applied successfully in the manufacturing of kilograms of GMP API.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available